Johnson & Johnson's IMAAVY Gains FDA Nod, Rivaling Myasthenia Gravis Giants Johnson & Johnson's latest drug, IMAAVY, has received FDA approval for treating myasthenia gravis, positioning the company against major market players. This article explores the implications.

Johnson & Johnson's IMAAVY Gains FDA Nod, Rivaling Myasthenia Gravis Giants #USA #Las_Vegas #Myasthenia_Gravis #IMAAVY #Johnson_Johnson